Investigation of the tolerability of oral stevioside in Brazilian hyperlipidemic patients

• Autor(a) principal: Silva,Gisleine Elisa Cavalcante da
• Data de Publicação: 2006
• Outros Autores: Assef,Abdol Hakin, Albino,Claudio Cordeiro, Ferri,Letícia de Araujo Funari, Tasin,Gilson, Takahashi,Mirian Hideko, Eik Filho,Wilson, Bazotte,Roberto Barbosa
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Brazilian Archives of Biology and Technology
• Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-89132006000500007
• topic: Stevia rebaudiana (Bert) Bertoni; stevioside; clinical investigation; placebo effect

The tolerability of stevioside (2.75 mg/kg/day) obtained from leaves of Stevia rebaudiana (Bert) Bertoni (Compositae) was investigated in hyperlipidemic patients. For this purpose a placebo controlled double blind study was performed. The patients were randomized in two groups: the first group received capsules containing placebo and the second group received capsules containing stevioside (50 mg) during 90 days. All capsules were ingested twice daily, i.e., 2 capsules before lunch and 2 capsules before dinner. After the selection of the patients and each 30 days body mass index and laboratory tests (alanine aminotransferase, aspartate aminotransferase, gamma-glutamyltransferase, total cholesterol, high density lipoprotein, low density lipoprotein, very low density lipoprotein, triglycerides and glucose) were performed. Stevioside did not show any clinical relevant modification in all parameters investigated. Moreover the patients did not report severe adverse effect. Thus, we can concluded that stevioside, at least in the doses employed in this study was safe.